Author:
Spellman Alison,Tang Shou-Ching
Publisher
Springer Science and Business Media LLC
Reference206 articles.
1. Finn, O. J. (2008). Cancer immunology. The New England Journal of Medicine, 358(25), 2704–2715. doi: 10.1056/NEJMra072739 .
2. Murphy, J. F. (2010). Trends in cancer immunotherapy. Clin Med Insights Oncol, 4, 67–80.
3. Fisher, R. I., Rosenberg, S. A., & Fyfe, G. (2000). Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. The Cancer Journal from Scientific American, 6(Suppl 1), S55–S57.
4. Eggermont, A. M., Suciu, S., Santinami, M., Testori, A., Kruit, W. H., Marsden, J., et al. (2008). Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet, 372(9633), 117–126. doi: 10.1016/S0140-6736(08)61033-8 .
5. Fyfe, G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., & Louie, A. C. (1995). Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. Journal of Clinical Oncology, 13(3), 688–696.
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献